` ANIP (ANI Pharmaceuticals Inc) vs S&P 500 Comparison - Alpha Spread

ANIP
vs
S&P 500

Over the past 12 months, ANIP has underperformed S&P 500, delivering a return of -4% compared to the S&P 500's 24% growth.

Stocks Performance
ANIP vs S&P 500

Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
ANIP vs S&P 500

Loading
ANIP
S&P 500
Difference

Performance By Year
ANIP vs S&P 500

Loading
ANIP
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
ANI Pharmaceuticals Inc vs Peers

S&P 500
ANIP
LLY
DPH
NOVO B
JNJ
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

ANI Pharmaceuticals Inc
Glance View

Market Cap
1.1B USD
Industry
Pharmaceuticals

ANI Pharmaceuticals Inc. operates at the heart of the pharmaceutical industry with a focused strategy that blends generics with niche high-value medications. Born in the realm of specialty pharmaceuticals, the company has crafted a business model that leverages both organic growth and strategic acquisitions. This dual approach helps the company to broaden its product offerings and maintain a robust pipeline. By targeting niche markets often overlooked by larger pharmaceutical giants, ANI maximizes its opportunities in areas with less competitive congestion. Central to its operations is the manufacturing and marketing of generic prescription products that are not only critically required but also pose less risk of commoditization due to their complexity, regulatory hurdles, or limited manufacturing capabilities. Revenue generation for ANI is a sophisticated blend of manufacturing, marketing, and brand positioning. The company's infrastructure supports integrated product development, regulatory approval, and scalable manufacturing processes. This allows them to efficiently bring to market a diverse portfolio of more than a hundred products across therapeutic areas. Additionally, ANI taps into revenue streams by producing legacy branded drugs often acquired from larger players looking to offload non-core assets. These legacy products, while sometimes in smaller volumes, benefit from loyal prescriber bases and established market presence, providing a steady income for the company. In essence, ANI Pharmaceuticals thrives on navigating the intricacies of the pharmaceutical supply chain, seizing opportunities in underexplored niches and refocusing the potential of undervalued brands.

ANIP Intrinsic Value
93.06 USD
Undervaluation 42%
Intrinsic Value
Price
Back to Top